Yes, the only reason why MX1 proceeded with the pathway of progressing their stroke CT was because of the $8m ASA grant. Without it, they would not have the funding to progress it.
Good luck to MX1 as the market is big enough and the goal is to ultimately save lives.
However, MX1 are years behind, and I have confidence in the EMV team will be out with a game changing device at least 3 years ahead of them.
EMvision Research Notes, page-1628
-
- There are more pages in this discussion • 1,091 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.00 |
Change
0.000(0.00%) |
Mkt cap ! $171.0M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.06 | $2.00 | $59.88K | 29.81K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15000 | $1.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 4830 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| EMV (ASX) Chart |